このページの翻訳は実験的なもので、現在開発中です。お待ちしております
China Resources Pharmaceutical Group マネジメント
マネジメント 基準チェック /34
China Resources Pharmaceutical Group'sの CEO はXiaosong Baiで、 Jan2022年に任命され、 の在任期間は 2.58年です。 の年間総報酬はCN¥ 3.60Mで、 98.6%給与と1.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.003%を直接所有しており、その価値はHK$ 1.10M 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と3.9年です。
主要情報
Xiaosong Bai
最高経営責任者
CN¥3.6m
報酬総額
| CEO給与比率 | 98.6% |
| CEO在任期間 | 2.8yrs |
| CEOの所有権 | 0.003% |
| 経営陣の平均在職期間 | 2.8yrs |
| 取締役会の平均在任期間 | 4yrs |
経営陣の近況
Recent updates
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥4b |
| Mar 31 2024 | n/a | n/a | CN¥4b |
| Dec 31 2023 | CN¥4m | CN¥4m | CN¥4b |
| Sep 30 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥3b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥2m | CN¥2m | CN¥4b |
報酬と市場: Xiaosongの 総報酬 ($USD 513.56K ) は、 Hong Kong市場 ($USD 737.91K ) の同様の規模の企業の平均を下回っています。
報酬と収益: Xiaosongの報酬は過去 1 年間で 20% 以上増加しました。
CEO（最高経営責任者
Xiaosong Bai (53 yo)
2.8yrs
在職期間
CN¥3,601,000
報酬
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Director | 2.8yrs | CN¥3.60m | 0.0032% CN¥ 1.2m | |
| VP & Executive Director | 3.1yrs | CN¥2.94m | データなし | |
| CFO & Executive Director | 1.3yrs | データなし | データなし | |
| Chief Information Officer & VP | 10.8yrs | データなし | データなし | |
| Company Secretary | less than a year | データなし | データなし | |
| Vice President | no data | データなし | データなし | |
| Vice President of CR Pharma & Chairman of China Resources Boya | no data | データなし | データなし |
2.8yrs
平均在職期間
53yo
平均年齢
経験豊富な経営陣: 3320の経営陣は 経験豊富 であると考えられます ( 2.6年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Director | 2.8yrs | CN¥3.60m | 0.0032% CN¥ 1.2m | |
| VP & Executive Director | 3.1yrs | CN¥2.94m | データなし | |
| CFO & Executive Director | less than a year | データなし | データなし | |
| Independent Non-Executive Director | 8.3yrs | CN¥270.00k | データなし | |
| Non-Executive Director | 2.8yrs | データなし | データなし | |
| Independent Non-Executive Director | 8.3yrs | CN¥270.00k | データなし | |
| Independent Non-Executive Director | 8.3yrs | CN¥270.00k | データなし | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 5.8yrs | データなし | データなし | |
| Non-Executive Director | 1.7yrs | データなし | データなし | |
| Independent Non-Executive Director | 7.2yrs | CN¥270.00k | データなし | |
| Chairman | 5yrs | データなし | 0.0048% CN¥ 1.8m | |
| Non-Executive Director | less than a year | データなし | データなし |
4.0yrs
平均在職期間
57yo
平均年齢
経験豊富なボード: 3320の 取締役会 は 経験豊富 であると考えられます ( 3.9年の平均在任期間)。